FIGURE 3.
Immune function pathway scores in 2 R (A and B) and 2 NR (C and D) patients are plotted to show how they vary across time during p53MVA/pembolizumab treatment. Lines show each pathway's score of its weighted mRNA expression levels data derived from the NanoString nCounter PanCancer Immune Profiling Panel analysis. Fluctuating changes in T cell and associated immune function categories are observed in 2 R but not in 2 NR patients.